Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that binds to and inhibits the binding of epidermal growth factor receptor (EGFR) (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it regulates epithelial tissue growth and homeostasis. EGFR has been related to more advanced disease and a bad prognosis in several types of cancer due to its overexpression in malignant cells. EGFR is frequently mutated in cancer and acts as a carcinogenesis driver. Cetuximab has been proven in vitro to have anti-tumor effects in a variety of cancer cell lines and human tumour xenografts. According to FDA criteria, approximately 75% of patients with metastatic colorectal cancer have an EGFR-expressing tumour and are thus eligible for therapy with cetuximab or panitumumab. Unfortunately, there is evidence that immunohistochemistry EGFR receptor testing doesn't really indicate responsiveness to either cetuximab or panitumumab, prompting insurers and even healthcare systems to withhold coverage for EGFR antibody care for people who do not have a positive tumour EGFR histochemical test. Cetuximab, which was approved by the FDA in February 2004 under the brand name ERBITUX, is used to treat head and neck cancer as well as metastatic, KRAS wild-type colorectal cancer and metastatic colorectal cancer with a BRAF V600E mutation. It has also been studied in advanced colorectal cancer, non-small cell lung cancer (NSCLC) with EGFR expression, and unresectable squamous cell skin carcinoma. Cetuximab is given intravenously and can be used alone or in conjunction with other chemotherapies such as platinum drugs, radiation treatment, leucovorin, fluorouracil, and irinotecan. The occurrence of acne-like rash is among the most significant side effects of cetuximab therapy. This rash seldom causes dose reductions or medication discontinuation. In most cases, it is reversible. Fever, chills, rigours, urticaria, itching, rash, hypotension, vertigo, vomiting, migraine, shortness of breath, asthma, angioedema, disorientation, anaphylaxis, and cardiogenic shock are all examples of severe infusion responses. Other typical side effects includes photosensitivity, hypomagnesemia from magnesium depletion, and, less frequently, pulmonary and heart toxicity.

Cetuximab is a monoclonal antibody that get together specifically to the EGFR on both normal and cancer cells, inhibiting the interaction of epidermal growth factor (EGF) as well as other ligands generated by normal and tumour epithelial cells. Cetuximab stops EGFR from assuming an expanded conformation, inhibiting EGFR activation as well as phosphorylation and activity of receptor-associated kinases, by attaching to domain III of EGFR, which is the essential cofactor for its growth factor ligands. Inhibiting the EGFR signalling pathway eventually inhibits cell growth, cell survival pathways, as well as tumour cell motility and invasion. Cetuximab also causes cell death and reduces the production of matrix metalloproteinase and vascular endothelial growth factor (VEGF).

An online search for the wholesale price for sale of Cetuximab for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Cetuximab distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Cetuximab suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Cetuximab. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Cetuximab is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturer's Cetuximab suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Cetuximab for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.